Perirenal Fat Diameter Measured by Echography Could Be an Early Predictor of Lipodystrophy in HIV Type 1--Infected Patients Receiving Highly Active Antiretroviral Therapy

Asensi, Victor; Martín-Roces, Eustaquio; Carton, José A.; Collazos, Julio; Maradona, José A.; Alonso, Angeles; Medina, Marifé; Aburto, Jesús M.; Martínez, Esteban; Rojo, Carmen; Bustillo, Enrique; Fernández, Cristina; Arribas, José M.
July 2004
Clinical Infectious Diseases;7/15/2004, Vol. 39 Issue 2, p240
Academic Journal
Echographically measured thicknesses of perirenal and subcutaneous fat, as well as serum metabolic and anthropometric parameters, were evaluated in 74 human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy (HAART), 22 of whom were HAART-naive at baseline, who were followed-up for 27 months to detect predictive factors of lipodystrophy. Perirenal fat diameter (PRFD) at baseline differed in HAART-naive and HAART-experienced patients (P < .001), and it was the best predictor of lipodystrophy changes after 12 months of follow-up in the HAART-naive patients (hazard ratio, 7.34; 95% confidence interval, 1.18- 45.49; P = .032). In addition, HAART-experienced patients in whom lipodystrophy improved had thinner baseline perirenal fat than those in whom lipodystrophy did not improve (P = .04). A PRFD of >2.6 mm at baseline or >4.9 mm during receipt of HAART suggested lipodystrophy predisposition. PRFD correlated significantly with other metabolic and anthropometric parameters. Echographically measured PRFD is associated with lipodystrophy and could be used as an early predictor of this syndrome in treatment-naive patients starting HAART.


Related Articles

  • Uridine Metabolism in HIV-1-Infected Patients: Effect of Infection, of Antiretroviral Therapy and of HIV-1/ART-Associated Lipodystrophy Syndrome. Domingo, Pere; Torres-Torronteras, Javier; Pomar, Virginia; Giralt, Marta; Domingo, Joan Carles; Gutierrez, Maria del Mar; Gallego-Escuredo, José M.; Mateo, Maria Gracia; Cano-Soldado, Pedro; Fernandez, Irene; Pastor-Anglada, Marçal; Vidal, Francesc; Villarroya, Francesc; Andreu, Antoni; Marti, Ramon // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Background: Uridine has been advocated for the treatment of HIV-1/HAART-associated lipodystrophy (HALS), although its metabolism in HIV-1-infected patients is poorly understood. Methods: Plasma uridine concentrations were measured in 35 controls and 221 HIV-1-infected patients and fat uridine in...

  • THE ROLE OF EXERCISE WITH HIV. Irwin, Melissa // HealthEX Specialist;2005, Issue 5, p9 

    Discusses the impact of exercise interventions on long-term effects of Human Immunodeficiency Virus (HIV) and Highly Active Antriretroviral Therapy (HAART) in Great Britain. Background on HIV and HAART; Overview of the long-term effects of HIV and HAART, including body fat redistribution or...

  • Rosigitazone Treatment for Fat Redistribution and Metabolic Abnormalities Caused by Anti-HIV Therapy.  // Annals of Internal Medicine;5/18/2004, Vol. 140 Issue 10, pI36 

    Presents questions and answers related to the article "Metabolic Effects of Rosiglitazone in HIV Lipodystrophy. A Randomized, Controlled Trial," from the same issue. Study of the possible use of the diabetes drug rosiglitazone to treat or prevent HIV lipodystrophy; Side effects of...

  • DisfuncÈ›ia endotelială, lipodistrofia ÅŸi sindromul metabolic la pacienÈ›i infectaÈ›i cu HIV. PAPIȚĂ, ANAMARIA; ALBU, ADRIANA; ITU, CORINA; CÂRSTINA, D. // Romanian Journal of Medical Practice;2010, Vol. 5 Issue 3, p185 

    HIV infection has become in our days a chronic disease due to the efficiency of antiretroviral (ARV) treatment. Soon after the introduction of this treatment its complications related to metabolic disturbances have been observed and studied. Metabolic syndrome was particularly described in...

  • Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. Collins, Evan J.; Burgoyne, Robert W.; Wagner, Cheryl A.; Abbey, Susan E.; Halman, Mark H.; Nur, Margaret L.; Walmsley, Sharon L. // AIDS & Behavior;May2006, Vol. 10 Issue 3, p273 

    Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample...

  • Correction Options for Lipoatrophy in HIV-Infected Patients. Engelhard, Peter // AIDS Patient Care & STDs;Mar2006, Vol. 20 Issue 3, p151 

    Lipoatrophy (LA) is a form of lipodystrophy, characterized by volume depletion caused by fat loss in the limbs, buttocks, and face. Facial volume loss is the most obvious outward sign of LA because it alters the facial contours in the cheeks, temples, and orbits. Lipodystrophy and LA are most...

  • Alteraciones metabólicas secundarias al tratamiento antirretroviral en niños infectados por VIH (primera parte). Noguera-Julian, Antoni; fortuny, Clàudia // Revista de Enfermedades Infecciosas en Pediatria;oct-dic2011, Vol. 25 Issue 98, p35 

    No abstract available.

  • Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. Sabin, Caroline A.; Weber, Rainer; Worm, Signe Westring; Reiss, Peter; Cazanave, Charles; El-Sadr, Wafaa; Monforte, Antonella D'Arminio; Fontas, Eric; Law, Matthew G.; Friis-Møller, Nina; Phillips, Andrew; De Wit, Stephane // Diabetes Care;Jun2008, Vol. 31 Issue 6, p1224 

    OBJECTIVE--The aims of this study were to determine the incidence of diabetes among HIV-infected patients in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort, to identify demographic, HIV-related, and combination antiretroviral therapy (cART)-related factors associated with...

  • A Randomized, Placebo-Controlled Trial of Rosiglitazone for HIV-Related Lipoatrophy. Cavalcanti, Rodrigo B.; Raboud, Janet; Shen, Sandy; Kain, Kevin C.; Cheung, Angela; Walmsley, Sharon // Journal of Infectious Diseases;6/15/2007, Vol. 195 Issue 12, p1754 

    Background. Thiazolidinediones such as rosiglitazone may have benefit in ameliorating human immunodeficiency virus (HIV) lipoatrophy. Methods. HIV-positive patients receiving stable, protease inhibitor-containing highly active antiretroviral therapy with HIV lipodystrophy were prospectively...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics